Novartis buys Singapore company developing IgA nephropathy drug

Novartis has agreed to buy SanReno Therapeutics, a clinical-stage company that specializes in the development of treatments for kidney diseases, according to a press release.
Established in late 2021 as a joint venture between investors and Chinook Therapeutics, now part of Novartis, SanReno Therapeutics holds exclusive rights in China and Singapore for atrasentan and zigakibart, two therapies that target immunoglobulin A nephropathy, according to the release.
Atrasentan is an oral endothelin A receptor antagonist in phase 3 trials. Zigakibart (BION-1301) is a subcutaneously administered

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.